The FDAs Division of Drug Marketing, Advertising and Communications has reviewed GE Healthcares Web site for its contrast agent, Visipaque (iodixanol) Injection, and deemed the promotional material misleading because it presents unsubstantiated comparative claims and omits and minimizes the risks associated with Visipaque.

A positive correlation between post-procedural myocardial injury and volume and fraction of low-attenuation plaque within target lesions measured by multidetector CT angiography after elective PCI was discovered by Tadayuki Uetani, MD, from the department of cardiology at Chubu Rosai Hospital in Nagoya, Japan, and colleagues.

Lantheus Medical Imaging has launched Ablavar (gadofosveset trisodium), an injectable MR angiography (MRA) imaging agent used to evaluate aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease.

Acute kidney injury occurred in 11.7 percent of patients following transcatheter aortic valve implantation (TAVI), and was associated with a greater than fourfold increase in the risk of postoperative mortality, according to a Canadian study published online Dec. 27 in the European Heart Journal.

Christie, a visual technologies company, has acquired all the assets of Luminetx, a medical biosciences technology company.

Cardiac MRI has distinguished itself as a tool for diagnosing heart disease, namely in examining the size and thickness of heart chambers, viewing the extent of damage from progressive heart disease, detecting plaque buildup and assessing a patients recovery following treatment.

Image quality of multi-detector CT scans, when utilized for the noninvasive detection of coronary artery stenosis, can be significantly associated with patient characteristics, including ethnicity, body mass index, heart rate and the presence of breathing artifact, but not with coronary artery calcium (CAC) score at a patient level, based on a study in the January issue of the American Journal of Roentgenology.

Lantheus Medical Imaging touted the benefits of its recently acquired MR angiography (MRA) agent, Ablavar (formerly marketed as Vasovist, gadofosveset trisodium), at the 2009 Radiological Society of North America in Chicago earlier this month.